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Abstract 
Background: Anti-hypertensives that modify the renin angiotensin system may reduce 
Alzheimer’s disease pathology and reduce the rate of disease progression. We report a 
phase II, two arm, double-blind, placebo-controlled, randomised trial (ISRCTN: 93682878; 
EudraCT: 2012-003641-15) of losartan to test the efficacy of Reducing pathology in 
Alzheimer’s Disease through Angiotensin TaRgeting (RADAR). 
Study population: Men and women aged at least 55 years with mild-to-moderate Alzheimer’s 
disease (AD) 
Interventions: Randomly allocated 100mg encapsulated generic losartan or placebo once 
daily for 12 months after successful completion of a 2 week open-label phase and 2 weeks 
placebo washout to establish drug tolerability. 
Outcomes: The primary outcome is the rate of whole brain atrophy as a surrogate measure of 
disease progression. Secondary outcomes include changes to (i) white matter hyperintensity 
(WMH) volume and cerebral blood flow (CBF) (also surrogate markers of cognitive decline 
and disease progression); (ii) performance on a standard series of assessments of memory, 
cognitive function, activities of daily living and quality of life.  
Assessments: Major assessments (for all outcomes) and relevant safety monitoring of blood 
pressure and bloods will be at baseline and 12 months. Additional cognitive assessment will 
also be conducted at 6 months along with safety blood pressure and blood monitoring. 
Monitoring of blood pressure, bloods and reported side effects will occur during the open-label 
phase and during the majority of the post-randomisation dispensing visits.  
Sample Size: 228 participants to provide at least 182 subjects with final assessments to 
provide 84% power to detect a 25% difference in atrophy rate (therapeutic benefit) change 
over 12 months at an alpha level of 0.05. 
Analysis: Intention-to-treat analysis, estimating between-group differences in outcomes 
derived from appropriate (linear or logistic) multivariable regression models adjusting for 
minimisation variables. 
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Background 
Currently the care costs of Alzheimer’s disease are almost equal to that of cancer, stroke and 
heart disease combined, and are predicted to increase in the current absence of long term 
effective therapies (1-3). Thus there remains urgent need for better treatments to extend the 
quality of life of patients, their carers and to reduce the rising associated health care costs. 
Any treatment delaying the onset of AD by 5 years could halve its prevalence (4).  
Hypertension in midlife (5, 6) and late life (7), and stroke (8) increase risk of dementia. 
Recently, we (9) and others (10) observed that angiotensin II (AngII) targeting drugs (AngII 
type 1 receptor antagonists (AT1RAs) and Angiotensin Converting Enzyme inhibitors (ACEIs) 
had lower incidence of AD compared with other types of anti-hypertensive drugs. AT1RAs 
were significantly more beneficial than ACEIs. While the underlying cause of AD remains 
unclear, loss of acetylcholine and neurons due to the deposition in the brain of amyloid-β (Aβ) 
peptide and tau pathology is key (11). Significant cerebrovascular pathology (CVP), such as 
reduced cerebral blood flow (CBF), loss of cerebrovascular autoregulation, ischaemia and 
white matter hyperintensities (WMHs); pathologies associated with and predictive of loss of 
cognitive function (12-16); is also common (11, 17, 18). Hypertension is associated with 
plasma levels of Aβ (19) and AD risk (20). Molecular pathways, likely independent of 
cerebrovascular mediated pathology are also probably relevant. Angiotensin converting 
enzyme (ACE) and neprilysin (NEP), which make AngII, are elevated in the AD brain (21, 22). 
ACE activity is elevated in peripheral blood in AD (23); ACE and NEP degrade Aβ in vitro and 
in vivo (2); variation in the ACE gene associated with lower plasma levels of ACE are also 
associated with AD risk (24). AngII promotes the synthesis of the inflammatory mediator 
TNFα (25, 26), and has anti-cholinergic (27, 28) and anti-glutamatergic effects (29), all of 
which are major sequelae of AD pathology. 
Losartan, an angiotensin type 1 receptor antagonist (AT1RA) is an effective anti-hypertension 
drug over a wide range of ages. Losartan crosses the blood brain barrier (30) and is of the 
class of AngII blocking drugs that we, and others, have observed to be associated with 
reduced incidence of AD (9, 10).  Losartan also improves CBF (14), a surrogate marker of 
cognitive performance in humans (31-33), and limits neuronal damage following ischaemia in 
stroke rat models (16); in low doses (i.e. not reducing blood pressure (BP)), it reduces 
pathology and improves cognitive performance in transgenic mouse models of AD (34). Given 
its anti-hypertensive effect it is also likely to reduce ischaemia-mediated WMHs (12).  
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No clinical trials studying losartan or any related AT1RA drugs as an intervention in AD have 
been undertaken to date. The most relevant related studies that used losartan (50mg) 
reported modest benefits, non-significant benefits on memory in non-demented hypertensive 
patients (35, 36), which were thought to be independent of BP-lowering effects (37). Yet, as a 
hypertension trial, cognition was not the primary outcome and thus was likely underpowered 
for more conventional study of cognition. To date, there are limited systematic reviews that 
have assessed the impact of BP-lowering on cognitive decline (38). McGuinness and 
colleagues previously concluded, based on data from four randomised controlled trials 
(RCTs), that BP reduction was insufficient to prevent dementia and cognitive decline in 
hypertensive patients with no prior cerebrovascular disease. This is supported by secondary 
analysis of ONTARGET and TRANSCEND where neither the ACEI (ramipril) nor another 
AT1RA (telmisartan) appeared to reduce the risk of cognitive decline and any type of 
dementia in patients with cardiovascular disease or diabetes (39). Staessen (2011) also 
reported in a meta-analysis of hypertension treatment trials, that BP-lowering did not reduce 
dementia risk in populations with high cardiovascular morbidity (40). In our opinion, these 
studies have limited scope for translation to the prognosis of AD since the study populations 
included were generally younger, selected according to high cardiovascular burden and 
cognitive assessment was not the primary outcome whereby assessment was generally less 
rigorous than that normally used in clinical trials of AD. In our opinion, these negative findings 
make any larger-scale (e.g. Phase III) multi-centre RCTs of an AT1RA in AD premature and 
currently unjustified without further supportive evidence.  
To our knowledge, no studies have investigated losartan on MRI measures of brain atrophy, 
CBF, WMH and cognition in AD. One related smaller (n=100) phase II three arm US-based 
trial (NCT00605072) was the antihypertensives and vascular, endothelial, and cognitive 
function (AVEC) trial. Using only hypertensive participants with early (non-AD) cognitive 
impairment, it compared one year of candesartan (AT1RA) treatment with lisinopril or 
hydrochlorothiazide for their effect on memory and executive function, CBF (measured by 
Transcranial Doppler) and central endothelial function (measured by changes in CBF in 
response to changes in end tidal carbon dioxide)(41).  
We have chosen losartan as our intervention because of the multi-factorial functions of AngII 
in the brain including vasoconstriction, reduction of acetylcholine (ACh) release, inflammation 
and neuronal excitotoxicity (25-29, 42). Second, selective antagonism of the AT1 receptor 
(AT1R) by losartan does not inhibit ACE activity, which may be important as ACE is elevated 
in AD (21, 22)) and can degrade Aβ (21, 43, 44). These preferential effects of AT1RAs over 
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ACE-inhibitors have been reviewed at length and are supported by various 
pharmacoepidemiological and pre-clinical studies (9, 10, 45-47). By testing an AT1RA in both 
hypertensive and normotensive AD patients, we enhance the generalizability of any finding 
and examine if any protective mechanisms may be operating independent of or in addition to 
BP-lowering effects.  
RADAR will test the hypothesis that AngII blockade in mild to moderate AD with 100mg of the 
AT1RA losartan will reduce the rate of brain volume loss and therefore slow the clinical 
progression of AD.  We have opted for the highest dose of losartan normally recommended 
and titrated directly from 25mg, reflecting standard clinical practice, to attempt maximal 
engagement of the intervention with its receptor whilst having provision of appropriate 
monitoring of blood pressure both prior to and during the course of the study.  
 
Study Design 
A two-arm, double-blind, placebo-controlled, multi-centre, randomised, trial comparing 100mg 
losartan or placebo effects. This will examine whether 12 months of treatment has any 
difference on changes in MRI brain imaging in AD patients (both hypertensive and 
normotensive).  
 
Study setting 
RADAR is a multi-centre study that is recruiting patients with mild-to-moderate AD from up to 
25 specialist hospital trusts where patients with AD are routinely diagnosed in the UK. Sites 
must have prior expertise in recruitment to clinical trials of AD and capacity to provide MRI 
facilities to fulfil the Neuroimaging protocol (see below) 
Inclusion criteria 
Patients diagnosed with mild-to-moderate AD according to original NINCDS-ADRDA criteria 
(48). Patients must have all of the following to be considered eligible: (i) Age ≥55 years (to 
maximise generalisability of the study and avoid exclusion of younger yet otherwise eligible 
potential participants); (ii) A MMSE score of 15-28; (iii) A modified Hachinski score (49) of 5 or 
less; (iv) A previous CT, SPECT or MRI scan consistent with a diagnosis of AD; (v) The 
presence of a study companion who is willing to participate in the study; (vi) Capacity to 
consent for themselves as judged by a member of the research team with appropriate training 
and experience. 
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Exclusion Criteria 
Patients will be ineligible if they have any of the following: (i) Receiving ACE-Inhibitors; 
AT1RAs, aliskiren or potassium sparing diuretics; (ii) Known intolerance or renal problems 
with ACE-inhibitors or sartans; (iii) Medically unsuitable for, or unwilling to have, an MRI scan; 
(iv) Consistent baseline BP of <115/70 mmHg or >160/110 mmHg; (v) A fall in BP on standing 
of >20/10 mmHg associated with clinically significant symptoms or a fall >30/15 mmHg; (vi) 
Previous cerebrovascular accident (CVA), with significant residual impairment (Transient 
Ischaemic Attack (TIA) is NOT an exclusion); (vii) Hypertrophic cardiomyopathy; or significant 
aortic valve stenosis; (viii) Estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73m2; 
(ix) Evidence of liver disease or significant LFT derangement (Aspartate transaminase (AST)/ 
Alkaline Phosphatase (AP/ALP)/ Bilirubin greater than 2 x upper limit of normal); (x) 
Potassium (K) greater than 6.0 mmol/L on non-haemolysed sample; (xi) Primary 
neurodegenerative diseases or potential causes of dementia other than AD; (xii) Females 
who have not yet reached the menopause (defined as having a period in the previous 12 
months) who test positive for pregnancy, are unwilling to take a pregnancy test prior to trial 
entry, or are unwilling to undertake adequate precautions to prevent pregnancy for the 
duration of the trial; (xiii) Any severe co-incident medical disease, or other factor inhibiting 
compliance with the study medication or follow up schedule e.g. participant unlikely to survive 
the trial follow up period due to a terminal comorbid condition; (xiv) Participation in a previous 
CTIMP within 6 months of RADAR trial entry. 
 
Intervention 
Participants will be randomised to either Losartan (100 mg) once a day or an identical looking 
placebo using over encapsulation (St. Mary’s Pharmaceutical Unit [SMPU]) for 12 months. 
Prior to randomization there is 3-4 week pre-randomised study open-label phase (See Figure 
1). This will involve potential participants being on open-label active drug for 14 days (7 days 
at 25mg followed by 7 days at 100mg) and then 4 to 14 days washout on a placebo. This is to 
ensure all patients entering the trial can tolerate the maximum dose of losartan (based on 
daily monitoring of BP over the open-label period in conjunction with any clinically relevant 
issues, including potential deviations from baseline blood measurements (as assessed by the 
Principle Investigator), or self-reported concerns made by participants or study companions) 
and have had a sufficiently long wash-out period to assess laboratory assessment of bloods 
prior to being randomised. There are no dose modifications after the participant has entered 
the randomised phase. Drug adherence is monitored by pill counts undertaken at the regular 
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follow-up visits (see figure 1). Normal clinical care is permitted including the use of other 
dementia related treatments requiring being on a stable dose for 3 months on study entry but 
allowing for naturalistic dose adjustment once entered. 
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Outcomes 
Primary measures 
Change in whole brain volume between MRI-based measured at both baseline and after 12 
months of treatment post randomisation, measured using volumetric MRI (vMRI). This is 
recognised as an empirical surrogate marker of cognitive decline and AD pathology (50-55). 
All MRI scans will be performed using either 1.5T or 3T imaging systems with high-resolution 
(1mm isotropic) 3D T1- MPRAGE at all sites. The volumetric analyses of the MPRAGE 
images will be conducted in collaboration with the Dementia Research Centre at University 
College London (UCL) who provided initial advice and validation of the MRI protocol at all 
sites. The UCL team have developed semi-automated computerised methods to derive brain 
structure volumes from single time-point MRI and rates of atrophy from serial MRI (56-59) 
similar to those previously reported for multi-centre trials(60). Quality control (QC) of scans 
and QC and editing of segmentations will be carried out using the MIDAS software (57). 
Automated segmentations will be performed using BMAPS (58) for brains and STEPS (61), 
prior to manual checks and edits by if needed. Image analysts undergo training and regular 
validation on structure segmentation. Longitudinal change following registration is measured 
using a Dementia Research Centre implementation of K-means normalised boundary shift 
integral (KN-BSI) (62) for brains or double window KN-BSI for the hippocampus (59, 62). 
 
Secondary measures 
These will include (i) rates of AD progression as assessed by changes in cognitive 
assessments (including MMSE), measures of activities of daily living and quality of life; (ii) 
change to the level of CBF measured by arterial spin labelling (ASL) techniques; (iii) change 
to the level of white matter hyperintensities by MRI; (iv) change in BP; (v) measure of 
association between MRI measures of atrophy and rate of cognitive decline; (vi) level of drug 
compliance and tolerability (particular consideration to non-hypertensive patients’ tolerability). 
ASL data will be processed using the NiftyFit software package (63) to generate quantitative 
CBF maps, and white matter hyperintensities automatically identified and quantified using 
dedicated software developed at UCL (64). 
 
An assessor whom will be blinded to the intervention will conduct face-to-face a schedule of 
assessments summarised in Table 1: 11 item ADAS-Cog (65); the Neuropsychiatry Inventory 
(NPI) (66); the Bristol Activities of Daily Living Scale (BADLS) (67), DEMQOL and DEMQOL-
Proxy (68). 
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Other imaging outcomes will include analysis of Cerebral Blood Flow (CBF) by arterial spin 
labelling (ASL) methods as a surrogate marker of cognitive performance as has already been 
reported in humans (31-33). Change in white matter hyperintensities (WMH) volume will be 
measured by T2/FLAIR to explore the efficacy of the trial medication in ameliorating white 
matter damage in participants, which has synergistic effects in AD (69) and predicts 1 year 
cognitive decline (12).  
The combination of measures of atrophy, CBF and WMH volume will be important 
complements to the standard cognitive assessment measures and may provide further 
mechanistic insights to justify further pursuit of losartan or other similar related drugs in large-
scale clinical trials of AD.  
Participant time line 
Participant pre-screening will be initially undertaken by examination of existing registers or 
after participants express their interest to take part, followed by a brief telephone check to 
ensure participants meet the basic criteria to warrant a visit to the research site where a face-
to-face interview with a clinician will take place. Consent will be taken at this visit and eligibility 
then confirmed after initial data collection. We have designed our inclusion criteria so that 
although the patients have a diagnosis of AD, they should still have capacity to consent, and 
they continue to have the right to withdraw consent in the future. If a participant loses capacity 
over the time of the trial, they will remain in the trial unless their legal representative (that may 
also be their companion) feels this is no longer appropriate. 
 
If a potential participant meets the eligibility criteria, they enter the open label phase (see 
figure 1). This establishes that they can tolerate 100 mg losartan (as described, see also 
Table 1) and there are no safety issues and hence reduces potential drop out secondary to 
either self-reported drug side effects, or clinically significant (as assessed by the Priniciple 
Investigator) deviation from protocol specified ranges of BP and blood measurement of 
electrolytes, creatinine and LFTs, after randomization. They then proceed to the baseline MRI 
and any patients who cannot have an MRI scan are then withdrawn. At this stage other 
baseline data is collected and randomization determines whether they are allocated to the 
active or placebo arm. There are then 6 further follow-up visits (hospital or home-based), 
mainly to ascertain safety and compliance though cognitive function is re-measured half way 
through the study at 6 months. At the 12 month visit they stop treatment and have a 4 day 
washout period before the repeat MRI scan and final assessments. (see table 1 for further 
details). At each visit, research staff will perform a capsule count and return any unused 
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medication to the site pharmacy. Participants who have taken between 80-120% of the 
expected number of tablets will be considered compliant (70). Non-compliance will be 
discussed with the Principal Investigator or delegated clinician to determine if it is appropriate 
to discontinue medication. 
 
In most cases data will be collected at a research clinic at the local site but in some cases, 
home visits may be undertaken. Patients who wish discontinue with the trail medication will be 
encouraged to stay in the trial and continue to be assessed so they can be included in the 
final analysis. 
 
Participant withdrawal 
Participants may voluntarily withdraw their consent for taking study medication at any time but 
may continue to be followed up if they wish.  
Participants may be withdrawn from the study medication at any time if deemed appropriate 
by the local PI due to adverse blood results, recognised drug-related side effects, loss of 
capacity and absence of legal representative to confirm continuing assent, the development 
of uncontrolled hypertension or hypotension that cannot be adequately managed without 
knowing whether the participant is on active therapy,  non-compliance with study medication, 
experience of a Serious Adverse Event or any other illness/disease developed through the 
course of the study making further participation inappropriate or requiring emergency 
unblinding 
 
Randomisation 
Randomizations were done by centres either telephoning or accessing an online centralised 
automated system (www.sealedenvelope.com) to ensure allocation concealment. We have 
used a stratified randomization approach using a minimization procedure to reduce allocation 
imbalance (whilst retaining a random component) stratified by age and baseline hippocampal 
volume according to Scheltens’ rating (71) and balanced according to site.  
 
Blinding 
All participants and study personnel (except Pharmacists) will be blinded to allocation by 
using over-encapsulation of losartan and placebo tablets. Assessment of MRI scans to 
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generate the primary outcome will be undertaken blinded to treatment arm. All the initial 
analyses will follow the statistical analysis plan and will maintain blinded codes for treatment 
status.  
Emergency unblinding can occur if a clinician believes that their treatment decision for a 
participant could be influenced if the patient was receiving losartan. A 24-hour emergency 
unblinding service is available to all research sites through each local pharmacy service within 
working hours and Out of Hours (OOH) either locally or by a pharmacy nominated by the 
study co-ordination team.  Requests for emergency unblinding will be documented by 
pharmacy staff and logged centrally by the Trial Manager. In the event that emergency 
unblinding has occurred, patients will discontinue taking the trial medication but remain part of 
the study unless they chose to withdraw. Where possible the members of the research 
team (excluding trial pharmacists) should remain blinded, subject always to clinical need. 
The Trial Manager will ascertain why unblinding has taken place. If the participant was 
unblinded because of a Serious Adverse Event (SAE) then the appropriate documentation will 
be completed and will be reported accordingly. Each participant will be given a Trial 
Participation Card with details of who their treating clinician should contact in the event of an 
emergency. 
 
Data entry 
All anonymised MRI data are uploaded and stored on a secure customised web-based server 
running XNAT 1.6.4 (www.xnat.org). Hard copies of anonymised paper based Case Report 
Forms (CRFs) are either sent to the Trial Co-ordinating team for data entry or directly entered 
onto a secure web-based database (REDCap 7.0.8 © Vanderbilt University).  
 
Monitoring and Adverse Events 
Safety monitoring will be conducted by the Chief Investigator (CI) and trial team and will 
report intermittently to a Data Monitoring and Ethics Committee (DMEC) that also reports to a 
Trial Steering Committee (TSC) that meets at least twice per year. The DMEC will examine 
data relating to trial processes, outcomes and adverse events.  The DMEC will comprise an 
independent chair and at least two other independent expert members including a medical 
statistician. The schedule of DMEC meetings will be staggered so that feedback is available 
for the TSC. 
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As the primary outcome only occurs at the end of follow-up, there are no planned interim 
analyses and no formal stopping rules as regards efficacy. If the DMEC has any concerns 
regarding safety they can forward their recommendation to the TSC who can review these at 
an unplanned TSC meeting and inform the trial management group and the sponsor whether 
they think the trial should be stopped prematurely. 
Participants are screened at each follow-up assessment for Adverse Events (AEs) as 
specified by the International Conference on Harmonisation [ICH] definition. Similarly blood 
pressure readings will be taken at most follow-up visits. Some of the more common tolerability 
issues include: dizziness, altered renal function indicated by adverse creatinine or electrolyte 
levels (allowing up to a 20% increase from baseline) or unresolved postural syncope. More 
detailed information on reported adverse events that have been reported for losartan used in 
this study are available online (http://www.tevauk.com/mediafile/id/40029.pdf); however, it has 
a low adverse event profile (72).   
Serious adverse events (SAEs), e.g. rarely occurring hypersensitivity or adverse reaction 
(AR) to the drug and Suspected Unexpected Serious Adverse Reactions (SUSARs), defined 
according to ICH definitions, will be reported and managed according to North Bristol NHS 
Research and Innovation Policies and Standard Operating Procedures. 
In the event of an incidental neuroimaging finding, we will follow the guidance set out in the 
recent “Management of Incidental Findings Detected in Research Imaging” report (see: 
https://www.rcr.ac.uk/docs/radiology/pdf/BFCR(11)8_Ethics.pdf). This is thought to be an 
unlikely occurrence as the inclusion criteria require that all patients should have had a 
previous CT or MRI scan which supported their diagnosis of AD. 
 
Enhancing site recruitment 
We will embed a qualitative component to the RADAR trial (before we have recruited 50% of 
the participants) to explore trial site recruitment, with the aim of enhancing the study design, 
conduct, organisation or training that could then lead to improvements in recruitment. 
Qualitative interviews will be undertaken with a purposeful sample of research nurses and 
doctors responsible for screening and consent and trial participants from a range of high and 
low recruiting trial sites to gain insights into barriers and facilitators for recruitment. With 
informed consent, interviews will be audio recorded, transcribed, and imported into NVivo 10 
and analysed thematically (73). Data collection and analysis will be conducted in parallel until 
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data saturation is reached (74).  The trial management group and the TSC will be informed of 
the findings. 
 
Sample Size and Analysis 
Our proposed sample size is based on previous studies conducted by the Alzheimer Disease 
Neuroimaging Initiative, (ADNI), which aim to optimise levels of recruitment to clinical trials of 
AD that involve MRI as an outcome measure (53, 55, 75). Previous data suggested a 12-
month atrophy rate among AD patients of 15.2 mL (SD 8.6 mL/year) and that a relative 
difference in between group atrophy rate of 25% is clinically meaningful. This is equivalent to 
an absolute difference in atrophy rate of 3.8 mL/year in total brain volume between the trial 
arms at 12 month follow up (76), and equivalent to a standardised effect size of 0.44 SDs. We 
will randomise a total of 228 participants that will leave 182 subjects for analysis assuming 
20% missing primary outcome data. This will provide us with 84% power to detect our target 
difference of 3.8 mL/year in 12 month atrophy (therapeutic benefit) with two-sided α = 0.05.  
The analysis and presentation of the trial results will be in accordance with CONSORT 
guidelines (http://www.consort-statement.org/), with the primary comparative analyses being 
conducted on an intention-to-treat basis and due emphasis placed on confidence intervals for 
the between-arm comparisons. A full analysis plan will be developed prior to completion of 
data collection, prior to commencing data analysis and will be approved by the Trial Steering 
Committee. 
Descriptive statistics of demographic and clinical measures will be used to examine balance 
between the arms at baseline. The primary comparative analyses will employ multivariable 
regression models to compare group mean atrophy rates at follow up, adjusted for baseline 
volume and stratification/ minimisation variables. The comparison will be presented as an 
absolute difference in mean 12-month atrophy rate in the losartan group compared with 
placebo, along with 95% confidence intervals. Similar analyses will be undertaken for the 
secondary outcomes (where p-values will be adjusted to account for multiple testing) and 
adjusting for any variables exhibiting marked imbalance at baseline to check that this does 
not influence the findings. There will be three additional types of analyses. First, we will 
undertake sensitivity analyses using both multiple imputation methods and simple methods 
making different assumptions to investigate the potential impact of missing data. Second, the 
effect of compliance with treatment will be investigated using allocation-respecting methods 
such as complier averaged causal effects (CACE) modelling. Third, appropriate interaction 
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terms will be entered into the primary regression analyses for atrophy rates in order to 
conduct pre-specified subgroup analyses according to baseline volume, previous history of 
hypertension and treatment on anti-dementia drugs. Since the trial is powered to detect 
overall differences between the groups rather than interactions of this kind, the results of 
these essentially exploratory analyses will be presented using confidence intervals and 
interpreted with due caution. 
Conclusion 
The RADAR trial is a phase II study that will provide evidence as to whether the AT1RA 
losartan does or does not influence the rate of brain volume loss in patients with early AD. 
Regardless of the results, it should provide valuable insights into potential mechanistic 
pathways and give further insight into the challenges of studying this patient group, as well as 
inform the relative merits of using brain atrophy as a marker for disease progress. If the 
findings are supportive of a potential neuroprotective effect, then a larger phase III is likely to 
be required to provide a more precise estimate of the clinical and quality of life benefits. As 
this drug is relatively safe and inexpensive (being off-license), even modest clinical benefits 
are likely to be cost-effective.  
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Table 1:  Summary of visits and assessments for RADAR trial 
Visit Researcher role Participant role 
Pre-Screening phase 
Early eligibility 
assessment 
Gather medication records to verify no 
potential drug conflicts 
 
Brief telephone assessment 
Consent on initial reply slip that medical records 
can be assessed to make sure there are no 
conflicts with the study medication 
Answer a few brief questions to ensure eligibility 
is likely for a face to face visit 
Screening Visit 
Eligibility 
Assessment 
Mini Mental State Exam (MMSE)* take 
baseline bloods for electrolytes, creatinine 
and LFTs 
Give consent of their intention to enter study 
subject to interview to ascertain eligibility, 
including blood levels check. Await confirmation 
to enter open-label phase (within 7 days from 
blood test) 
Follow up 
phone call 
(within 7 days 
of eligibility 
assessment 
Feedback blood test results and confirm 
whether patient can proceed. If suitable, 
arrange for collection of study medication 
and BP machine 
Collection of study medication by participant or 
companion 
Open Label Phase 
N/A N/A Take 25mg dose of drug for 7 days, maintain 
diary of BP check, drug taking and any side 
effects 
7 day visit Measure Sitting and Standing BP, take 
bloods for safety tests**, do pill count and 
provide next trial drug 
Take 100mg of drug for 7 days, maintain diary of 
BP check, drug taking and any side effects 
14 day visit Measure Sitting and Standing BP, take 
bloods for safety tests**, do pill count and 
provide next trial drug 
Start taking placebo drug for at least 4 days until 
called for baseline MRI visit  
Randomisation Phase 
Baseline Visit 
18-28 days 
after open 
label 
medication 
commenced) 
MRI to inform randomisation and collect 
primary outcome measure. At same visit or 
within 10 days conduct cognitive 
assessment***; Measure Sitting and 
Standing BP, take bloods for safety tests** 
and optional samples for future research 
and provide allocated drug (week 1 25mg, 
week 2 100mg)  
Take allocated drug  
14 days after 
randomisation 
Measure Sitting and Standing BP, take 
bloods for safety tests**; optional samples 
for future research, do pill count & provide 
next trial drug 
Take allocated drug  
3 months after 
randomisation 
Measure Sitting and Standing BP; take 
bloods for safety tests**, do pill count & 
provide next trial drug 
Take allocated drug  
6 months after 
randomisation 
Cognitive assessment***, measure Sitting 
and Standing BP, take bloods for safety 
tests**, do pill count & provide next trial 
drug  
Take allocated drug 
9 months after 
randomisation 
Sitting and Standing Measure BP; do pill 
count & provide next trial drug (no bloods to 
be taken at this time) 
Take allocated drug  
12 months 
after 
randomisation 
Initiate contact to participant to stop taking 
trial drug to provide at least 4 study drug 
free days (no dose reduction is required). 
Stop taking allocated drug 
End of Study 
12 months + 4 
days after 
randomisation  
MRI & MMSE. At same visit or within 10 
working days conduct cognitive 
assessment***, measure Sitting and 
Standing BP, take bloods for safety tests**; 
optional samples for future research; do 
final pill count.  
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* MMSE will be compared between eligibility screening visit and end of study. ** Blood safety tests will include 
measures of electrolytes, creatinine and LFTs according to protocol defined ranges for inclusion/exclusion 
***Cognitive assessment will include ADAS-COG (participant), NPI (companion), BADLS (companion), DEMQOL 
(participant) and DEMQOL-Proxy (companion).  
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Figure 1: Participant procedures and data collection after ascertainment of eligibility and 
willingness to participate. 
 
Time Data collection
Excluded if not able to 
tolerate medication
Excluded if not able to have 
MRI scan
Day 1 Medical history, MRI, 
cognitive assessments, safety 
& optional research bloods
Placebo Losartan
Day 14 Safety bloods, BP & optional 
research bloods
Month 3 Compliance, bloods & BP 
Month 6 Cognitive measures, 
compliance, bloods & BP
Month 9 Compliance & BP
Month 12
4-7 days 
post end 
of RCT
MRI measures, cognitive 
assessments & safety & 
optional  research bloods, BP 
and final pill count
At least 4 days washout on encapsulated placebo 
Follow-up assessment and start drug washout
Final assessment
Baseline MRI 
Baseline assessments and randomisation
Follow-up assessment
Follow-up assessment
Follow-up assessment
Follow-up assessment
Safety bloods after 7 and 14 
days
Patients eligible and willing to enter study
Open label phase
7 days on 25 mg losartan 1x/day
7 days on 100 mg losartan 1x/day
